Look at the "P" value for the study your using as a reason to NOT use ADEX!
1) The study cited was conducted using Letrozole
2) The "P" value was SF @ (0.002) compared to placebo
3) The study was designed to investigate the effect of Letrozole on "glucose metabolism and leptin levels"
4) The IGF changes were statistically significant but when one also considers the variability of IGF was so broad, approximating 300ng/ml, causation can NOT be ascertained.
For example contrast the younger patient control group IGF levels at,
study day ONE. The IGF average was 477+ -146 ng/ml
study day TWENTY EIGHT. The IGF average was 404 + - 143 ng/ml
THE AVERAGE change was a lowering of IGF by 73 ng/ml.
However considering a difference of as much as + - 150 ng/ml, not ALL NINE younger patients actually experienced a decline in IGF and in fact the data shown clearly suggests IGF actually INCREASED IN SOME YOUNGER PATIENTS.
What this means is the variance observed (some patients increased their IGF while others decreased it) is probably due to the patients themselves rather than the LETRO although perhaps in some younger males LETRO MAY be ASSOCIATED with a reduction on IGF, especially at HIGHER DOSES. (My contention since physiologically an decreasing E-2 suppresses GH secretion)
All that being said I seriously doubt a change of IGF of 10-15% would alter anabolism significantly much like similar changes in TT.
Thanks ASAF
JIM
1) The study cited was conducted using Letrozole
2) The "P" value was SF @ (0.002) compared to placebo
3) The study was designed to investigate the effect of Letrozole on "glucose metabolism and leptin levels"
4) The IGF changes were statistically significant but when one also considers the variability of IGF was so broad, approximating 300ng/ml, causation can NOT be ascertained.
For example contrast the younger patient control group IGF levels at,
study day ONE. The IGF average was 477+ -146 ng/ml
study day TWENTY EIGHT. The IGF average was 404 + - 143 ng/ml
THE AVERAGE change was a lowering of IGF by 73 ng/ml.
However considering a difference of as much as + - 150 ng/ml, not ALL NINE younger patients actually experienced a decline in IGF and in fact the data shown clearly suggests IGF actually INCREASED IN SOME YOUNGER PATIENTS.
What this means is the variance observed (some patients increased their IGF while others decreased it) is probably due to the patients themselves rather than the LETRO although perhaps in some younger males LETRO MAY be ASSOCIATED with a reduction on IGF, especially at HIGHER DOSES. (My contention since physiologically an decreasing E-2 suppresses GH secretion)
All that being said I seriously doubt a change of IGF of 10-15% would alter anabolism significantly much like similar changes in TT.
Thanks ASAF
JIM